Target intersection analysis shows that APN modulates TNF-α and IL-6 through AdipoR1/2 (Fig. 4A, F-G), so AdipoRon, a dual agonist of AdipoR1/2 [46], potentially plays a crucial part in anti-inflammatory effects and alleviates CD symptoms by reducing the levels of TNF-α and IL-6. Here, TNF is linked to Cowden disease.